LANXESS to keep Envalior JV after Advent HoldCo withdraws offer
Last update on Mar 17, 2026
Advent HoldCo will in 2026 not acquire the LANXESS stake in the ENVALIOR joint venture that LANXESS had tendered in September 2025. Advent HoldCo has now informed the specialty chemicals company accordingly, referring to its contractually agreed financing condition. As a result, the additional tender and purchase periods for LANXESS’ shares in ENVALIOR in the years 2027 and 2028 now apply, as described in the ad hoc announcement of September 23, 2025.
Catch up on all of Envalior's latest developments - visit their profile now!
Key drivers include market recovery and synergy between companies
LANXESS will continue to play an active role as a committed joint venture partner in shaping the expected positive development of ENVALIOR. According to LANXESS, key drivers of this development include the recovery of the market, synergy effects between the two companies brought into the joint venture as well as consolidation among direct competitors.
Even without proceeds from a sale of its ENVALIOR stake in 2026, LANXESS is solidly financed. The company holds a strong cash position as well as undrawn, firmly committed credit lines totaling more than EUR 1.35 billion. Therefore, repayment of the bond maturing in October 2026 is already ensured. The financing instruments are not subject to any financial covenants.
In addition, LANXESS continues to have unrestricted and broad access to the debt capital markets.
Reducing financial debt remains a high priority for LANXESS.
LANXESS will publish its financial results for the year 2025 on March 19, 2026.